KB Insurance Obtains Exclusive Rights for Thyroid Cancer Hormone Medication Approval Treatment Costs

[Asia Economy Reporter Oh Hyung-gil] KB Insurance announced on the 19th that its 'Thyroid Cancer Hormone Drug Authorization Treatment Cost' coverage has obtained an exclusive usage right from the General Insurance Association for three months.

The Thyroid Cancer Hormone Drug Authorization Treatment Cost coverage pays insurance benefits only once upon the first occurrence if a diagnosis of thyroid cancer is confirmed during the insurance period and the insured receives 'thyroid cancer hormone drug authorization treatment' after thyroid cancer surgery.

Thyroid cancer is a disease with a good prognosis, with a 5-year survival rate approaching 100%, as most cases are detected early through health checkups and treated effectively through surgery. However, about 90% of thyroid cancer surgery patients need to continuously take thyroid hormone medication after surgery to prevent recurrence.

KB Insurance has expanded its cancer treatment coverage area to include the recurrence prevention stage after chemotherapy and surgery by developing the Thyroid Cancer Hormone Drug Authorization Treatment Cost coverage.

The Thyroid Cancer Hormone Drug Authorization Treatment Cost coverage is included in KB Insurance's representative cancer insurance product, 'KB Cancer Insurance and Living Healthily Story,' which also obtained exclusive usage rights in June last year for thyroid needle biopsy tissue pathology diagnosis costs, covering from thyroid cancer examination, diagnosis, treatment, hospitalization, surgery, to recurrence prevention.

A KB Insurance official stated, "We have established a paradigm of enhanced coverage areas from disease prevention to post-treatment recurrence prevention," adding, "We will continue to develop innovative products that can lead the market by reflecting customer needs."

This content was produced with the assistance of AI translation services.